戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ne or cromolyn), or a neurokinin antagonist (spantide).
2                    B6 mice were treated with spantide, and after infection, slit lamp examination; cl
3 P (SP), were treated with the SP antagonist, Spantide I (with/without Mphi depletion), resulting in e
4               Subconjunctival inoculation of spantide I during the clinical phase of HSK resulted in
5  major receptor (NK1-R) using the antagonist spantide I in susceptible mice infected with Pseudomonas
6                                         With Spantide I present, MCN1 no longer elicited the gastric
7 P (SP) binding to neurokinin 1 receptor with spantide I prevents Pseudomonas aeruginosa-induced corne
8 , we used the tachykinin receptor antagonist Spantide I to eliminate the actions of CabTRP Ia.
9               Subconjunctival inoculation of spantide I, SP receptor antagonist, was carried out duri
10 eu10]-substance P(7-11) and a SP antagonist, spantide I.
11 ropeptides in vitro, but was not affected by spantide I. mRNA for neurokinin-1-receptor-1 (NK-1R) was
12 ned delivery of two anti-inflammatory drugs, spantide II (SP) and ketoprofen (KP) on the skin permeat
13                                              Spantide II (SP) and ketoprofen (KP) were used as model
14           The SP receptor (SPR) antagonists, spantide II and RP-67,580, block both the initiation of
15                         Mice pretreated with spantide II and then orally inoculated developed advance
16  nonsubstance P receptor-mediated effects of spantide II on macrophages.
17                               Treatment with spantide II significantly reduced early Salmonella-induc
18 ent of mice with the substance P antagonist, spantide II, before oral inoculation with Salmonella.
19 ptibility to salmonellosis was not due to 1) spantide II-induced alterations in the uptake of this pa
20 ake of this pathogen from the gut, 2) global spantide II-mediated immune suppression, or 3) nonsubsta
21 sting a mechanism for the reduced ability of spantide II-treated mice to resist this pathogen.
22                            The SP antagonist Spantide provides a novel approach to reduce type 1 and
23                                              Spantide treatment of B6 mice significantly decreased th
24                                              Spantide treatment of Mphis reduced IL-1beta after LPS+S
25 as TGF-beta mRNA levels were unchanged after spantide treatment.
26 otein) also were significantly reduced after spantide treatment.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。